Geode Capital Management LLC Has $849,000 Stake in Monopar Therapeutics Inc. (NASDAQ:MNPR)

Geode Capital Management LLC boosted its position in shares of Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) by 174.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 38,596 shares of the company's stock after purchasing an additional 24,530 shares during the quarter. Geode Capital Management LLC owned approximately 0.63% of Monopar Therapeutics worth $849,000 at the end of the most recent reporting period.

Separately, JPMorgan Chase & Co. purchased a new stake in Monopar Therapeutics during the fourth quarter valued at about $45,000. Institutional investors and hedge funds own 1.83% of the company's stock.

Insider Buying and Selling

In related news, major shareholder Tactic Pharma Llc sold 33,334 shares of the business's stock in a transaction that occurred on Wednesday, April 2nd. The shares were sold at an average price of $35.00, for a total transaction of $1,166,690.00. Following the completion of the sale, the insider now directly owns 822,255 shares of the company's stock, valued at $28,778,925. The trade was a 3.90 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 34.90% of the stock is owned by corporate insiders.

Monopar Therapeutics Trading Down 3.6 %

Monopar Therapeutics stock traded down $1.60 during mid-day trading on Monday, hitting $43.36. 15,543 shares of the company's stock were exchanged, compared to its average volume of 359,038. Monopar Therapeutics Inc. has a 1-year low of $1.72 and a 1-year high of $54.30. The stock has a 50 day moving average of $35.92 and a two-hundred day moving average of $30.10. The stock has a market cap of $265.15 million, a P/E ratio of -22.01 and a beta of 1.11.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last released its earnings results on Monday, March 31st. The company reported ($2.23) EPS for the quarter, missing the consensus estimate of ($0.36) by ($1.87). As a group, research analysts predict that Monopar Therapeutics Inc. will post -1.65 EPS for the current fiscal year.

Analyst Ratings Changes

MNPR has been the topic of several analyst reports. Piper Sandler reaffirmed an "overweight" rating and set a $76.00 price target on shares of Monopar Therapeutics in a research note on Wednesday, March 19th. Jones Trading reiterated a "hold" rating on shares of Monopar Therapeutics in a research note on Wednesday, April 2nd. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $40.00 price objective on shares of Monopar Therapeutics in a report on Tuesday, April 1st.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.